LU-002C is a small molecule inhibitor categorized as a covalent proteasome inhibitor, used extensively in preclinical research to investigate protein degradation pathways and the mechanisms of cancer cell… Read more
LU-002C is a small molecule inhibitor categorized as a covalent proteasome inhibitor, used extensively in preclinical research to investigate protein degradation pathways and the mechanisms of cancer cell death. As research advances into the therapeutic potential of this compound, the availability of precise reference materials is essential for robust analytical testing. This category provides access to related compounds, including specific impurities such as trifluoroacetate salts, which are critical for impurity profiling and method validation during development. Furthermore, stable isotope labelled compounds like LU-002c-d7 and LU-012c-d7 serve as internal standards for mass spectrometry quantification, ensuring high accuracy in pharmacokinetic studies. By utilizing these metabolites and high-quality reference standards, pharmaceutical laboratories can effectively monitor drug metabolism, assess bioavailability, and ensure rigorous quality control throughout the evaluation of these complex proteasome-targeting agents.